Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 891907 10.3389/fphar.2022.891907 Pharmacology Correction Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study Chen et al. Corrigendum: Transition From Ambrisentan to Macitentan Chen Yusi 1 Luo Jun 1 Chen Jingyuan 1 Kotlyar Eugene 2 Li Zilu 1 Chen Wenjie 1 Li Jiang 1 * 1 Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, Changsha, China 2 St. Vincent’s Hospital, Sydney, NSW, Australia

Edited and reviewed by: Kevin Lu, University of South Carolina, United States

 *Correspondence: Jiang Li, lijiangcs@csu.edu.cn

This article was submitted to Drugs Outcomes Research and Policies, a section of the journal Frontiers in Pharmacology

 11 04 2022 2022 13 891907 08 03 2022 15 03 2022 Copyright © 2022 Chen, Luo, Chen, Kotlyar, Li, Chen and Li. 2022 Chen, Luo, Chen, Kotlyar, Li, Chen and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study by Chen, Y., Luo, J., Chen, J., Kotlyar, E., Li, Z., Chen, W. and Li, J. (2022). Front Pharmacol. 12:811700. doi:10.3389/fphar.2021.811700 pulmonary arterial hypertension macitentan ambrisentan endothelin receptor antagonist real-word study

In the original article, there was a mistake in Table 1 and in the Section Results, Patients’ Clinical Characteristics as published. “There were errors in the values for the ‘Ambrisentan dose’ as it was reported that one hundred and twenty-eight patients (88.3%) were receiving 10 mg once per day, whereas seventeen patients (11.7%) were receiving 5 mg once daily. This was corrected to sixty-one patients (42.1%) were receiving 10 mg once per day, and eighty-four patients (57.9%) were receiving 5 mg once daily.” The corrected Table 1 appears below and the text in the Section Results, Patients’ Clinical Characteristics has been updated.

Baseline characteristics.

Characteristic All patients (N = 145)
Age, years a 32.0 (26.0, 42.0)
Sex, n (%)
 Female 108 (74.5)
 Male 37 (25.5)
Duration of ambrisentan treatment before transition, years a 1.5 (1.0, 2.9)
 mPAP, mmHg b , c 61.4 ± 18.6
 PVR, Wood a , c 14.4 (8.0, 22.1)
 mRAP, mmHg b , c 10.0 ± 5.8
 mRVP, mmHg b , c 41.7 ± 12.4
Etiology of PAH, n (%)
 Idiopathic 32 (22.1)
 Drug or toxin-induced 4 (2.8)
 Associated with connective tissue disease 21 (14.4)
 Associated with congenital heart disease 88 (60.7)
Ambrisentan dose, mg, QD
 5 n (%) 84 (57.9)
 10 n (%) 61 (42.1)
WHO FC, n (%)
 II 85 (58.6)
 III 60 (41.4)
BMI (kg/m2) b 21.0 ± 3.2
PAH medications in addition to taking ambrisentan, n (%)
 Monotherapy 18 (12.4)
 PDE-5i 122 (84.1)
 Riociguat 4 (2.8)
 Riociguat and PDE-5i 1 (0.7)

Data are described as medians and interquartile ranges (non-normal distribution).

Data are described as means and standard deviations (normal or approximately normal distribution).

Historical data from the most recent right heart catheterization before enrollment.

mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; mRAP, mean right atrial pressure; mRVP, mean right ventricular pressure; QD, once per day; PAH, pulmonary arterial hypertension; WHO FC, World Health Organization functional class; BMI, body mass index; PDE-5i, phosphodiesterase type 5 inhibitor.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.